Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Cell

Volumn 86, Issue 3, 1996, Pages 353-364

  Hanahan, Douglas ^a   Folkman, Judah ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; APOPTOSIS; BASEMENT MEMBRANE; BLOOD VESSEL; BREAST CANCER; CARCINOGENESIS; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SUPPRESSOR GENE; TRANSGENIC MOUSE; UTERINE CERVIX CANCER;

MUS MUSCULUS;

EID: 0030576517     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)80108-7     Document Type: Review

References (80)

1. Adams, J.M., and Cory, S. (1991). Transgenic models of tumor development. Science 254, 1161-1167.
2. Arbeit, J.M. (1996). Transgenic models of epidermal neoplasia and multistage carcinogenesis. Cancer Surv., 26, 7-34.
3. Arbeit, J., Munger, K., Howley, P., and Hanahan, D. (1994). Progressive squamous epithelial neoplasia in K14-HPV16 transgenic mice. J. Virol. 68, 4358-4368.
4. Arbeit, J.M., Olson, D., and Hanahan, D. (1996). Upregulation of fibroblast growth factors and their receptors during multistage epidermal carcinogenesis in K14-HPV16 transgenic mice. Oncogene, in press.
5. Auerbach, W., and Auerbach, R. (1994). Angiogenesis inhibition: a review. Pharmacol. Ther. 63, 265-311.
6. Baird, A., and Ling, N. (1987). Fibroblast growth factors are present in the extracellular matrix produced by endothelilal cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response. Biochem. Biophys. Res. Commun. 142, 428-435.
7. Bouck, N., Stellmach, V., and Hsu, S. (1996). How tumors become angiogenic. Adv. Cancer Res. 69, in press.
8. Brem, S., Brem, H., Folkman, J., Finkelstein, D., and Patz, A. (1976). Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res. 36, 2807-2812.
9. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164.
10. Brouty-Boye, D., and Zetter, B.R. (1980). Inhibition of cell motility by interferon. Science 208, 516-518.
11. Brown, L.F., Berse, B., Jackman, R.W., Tognazzi, K., Guidi, A.J., Dvorak, H.F., Senger, D.R., Connolly, J.L., and Schnitt, S.J. (1995). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. 26, 86-91.
12. Brown, L.F., Detmar, M., Claffey, K., Nagy, J.A., Feng, D., Dvorak, A.M., and Dvorak, H.F. (1996). Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. In Control of Angiogenesis, I.D. Goldberg and E. Rosen, eds. (Berlin: Birkhauser Verlag), in press.
13. Christofori, G. (1996). The role of fibroblast growth factors in tumour progression and angiogenesis. In Tumour Angiogenesis, R. Bicknell, C.E. Lewis, and N. Ferrara, eds. (Oxford: Oxford University Press), in press.
14. Christofori, G., Naik, P., and Hanahan, D. (1994). Insulin-like growth factor II is focally up-regulated and functionally involved as a cofactor in oncogene-induced tumorigenesis. Nature 369, 414-418.
15. Christofori, G., Naik, P., and Hanahan, D. (1995a). Deregulation of both imprinted and expressed alleles of the IGF-II gene during β-cell tumorigenesis. Nature Genet. 10, 196-201.
16. Christofori, G., Naik, P., and Hanahan, D. (1995b). Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol. Endocrinol. 9, 1760-1770.
17. Clapp, C., Martial, J.A., Guzman, R.C., Rentier-Delrue, F., and Weiner, R.I. (1993). The 16 kDa N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinol. 133, 1292-1299.
18. Cockerill, G.W., Gamble, J.R., and Vadas, M.A. (1995). Angiogenesis: models and modulators. Int. Rev. Cytol. 159, 113-160.
19. Coussens, L.M., Hanahan, D., and Arbeit, J. (1996). Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am. J. Path., in press.
20. Dameron, K.M., Volpert, O.V., Tainsky, M.A., and Bouck, N. (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582-1584.
21. Engerman, R.L., Pfaffenbacvh, D., and Davis, M.D. (1967). Cell turnover of capillaries. Lab. Invest. 17, 738-743.
22. Ferrara, N. (1993). Vascular endothelial growth factor. Trends Cardiovasc. Med. 3, 244-250.
23. Ferrera, N., Clapp, C., and Weiner, R.I. (1991). The 16 kDa fragment of prolactin specifically inhibits basal or fibroblast growth factor-stimulated growth of capillary endothelial cells. Endocrinol. 129, 896-900.
24. Folkman, J. (1995a). Tumor angiogenesis. In The Molecular Basis of Cancer, J. Mendelsohn, P.M. Howley, M.A. Israel, and L.A. Liotta, eds. (Philadelphia: W.B. Saunders Co.), pp. 206-232.
25. Folkman, J. (1995b). Clinical applications of research on angiogenesis. N. Engl. J. Med. 333, 1757-1763.
26. Folkman, J., and Shing, Y. (1992). Angiogenesis. J. Biol. Chem. 267, 10931-10934.
27. Folkman, J., Klagsbrun, M., Sasse, J., Wadzinski, M., Ingber, D., and Vlodavsky, I. (1988). A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am. J. Pathol. 130, 393-400.
28. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61.
29. v integrins. Science 270, 1500-1502.
30. Friesel, R.E., and Maciag, T. (1995). Molecular mechanisms of angiogenesis: fibroblast growth factor signal. FASEB J. 9, 919-925.
31. Frost, P., Hart, I., and Kerbel, R.S. (1995). Cancer and metastasis reviews - transgenic mice. Cancer Metastasis Rev. 14, 77-161.
32. Gimbrone, M.A.J., Leapman, S.B., Cotran, R.S., and Folkman, J. (1972). Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136, 261-276.
33. Good, D.J., Polverini, P.J., Rastinejad, F., Le Beau, M.M., Lemons, R.S., Frazier, W.A., and Bouck, N.P. (1990). A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87, 6624-6628.
34. Goto, F., Goto, K., Weindel, K., and Folkman, J. (1993). Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab. Invest. 69, 508-517.
35. Grimmond, S., Lagercrantz, J., Drinkwater, C., Silins, G., Townson, S., Pollock, P., Gotley, D., Carson, E., Rakar, S., Nordenskjold, M., Ward, L., Hayward, N., and Weber, G. (1996). Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res. 6, 124-131.
36. Guidi, A.J., Fischer, L., Harris, J.R., and Schnitt, S.J. (1994). Microvessel density and distribution in ductal carcinoma in situ of the breast. J. Natl. Cancer Inst. 86, 614-619.
37. Guidi, A.J., Abu-Jawdeh, G., Berse, B., Jackman, R.W., Tognazzi, K., Dvorak, H.F., and Brown, L.F. (1995). Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J. Natl. Cancer Inst. 87, 1237-1245.
38. Gupta, S.K., Hassel, T., and Singh, J.P. (1995). A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor-4. Proc. Natl. Acad. Sci. USA 92, 7799-7803.
39. Hanahan, D. (1985). Heritable formation of pancreatic β cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315, 115-321.
40. Hanahan, D. (1988). Dissecting multistep tumorigenesis in transgenic mice. Annu. Rev. Genet. 22, 479-519.
41. Hanahan, D. (1989). Transgenic mice as probes into complex systems. Science 246, 1265-1275.
42. Hobson, B., and Denekamp, J. (1984). Endothelial proliferation in tumors and normal tissues: continuous labeling studies. Br. J. Cancer 49, 405-413.
43. Holmgren, L., O'Reilly, M.S., and Folkman, J. (1995). Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1, 149-153.
44. Homandberg, G.A., Williams, J.E., Grant, D., Schumacher, B., and Eisenstein, R. (1985). Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Am. J. Pathol. 120, 327-332.
45. Hurlin, P.J., Foley, K.P., Aver, D., Eisenman, R.N., Hanahan, D., and Arbeit, J.M. (1995). Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. Oncogene 11, 2487-2501.
46. Joukov, V., Pasujola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N., and Alitalo, K. (1996). A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2)receptor tyrosine kinases. EMBO J. 15, 290-298.
47. Kandel, J., Bossy-Wetzel, E., Radvany, F., Klagsbrun, M., Folkman, J., and Hanahan, D. (1991). Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66, 1095-1104.
48. Lacey, M., Alpert, S., and Hanahan, D. (1986). The bovine papillo-mavirus genome elicits skin tumours in transgenic mice. Nature 322, 609-612.
49. Lee, J., Gray, A., Yuan, J., Luoh, S.-M., Avraham, H., and Wood, W.I. (1996). Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt-4. Proc. Natl. Acad. Sci. USA 93, 1988-1992.
50. Millauer, B., Shawver, L.K., Plate, K.H., Risau, W., and Ullrich, A. (1994). Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-579.
51. Naik, P., Christofori, G., and Hanahan, D. (1994). Insulin-like growth factor II is focally up-regulated and functionally involved as a second signal for oncogene-induced tumorigenesis. In The Molecular Genetics of Cancer (Cold Spring Harbor, New York: Cold Spring Harbor Symposia on Quantitative Biology), pp. 459-471.
52. Nelson, J., Allen, W.E., Scott, W.N., Bailie, J.R., Walker, B., McFerran, N.V., and Wilson, D.J. (1995). Murine epidermal growth factor (EGF) fragment (33-42) inhibits both EGF- and laminin-dependent endothelial cell motility and angiogenesis. Cancer Res. 55, 3772-3776.
53. Olofsson, B., Pajusola, K., Kaipainen, A., von Euler, G., Joukov, V., Saksela, O., Orpana, A., Pettersson, R.F., Alitalo, K., and Eriksson, U. (1996). Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. USA 93, 2576-2581.
54. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H., and Folkman, J. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
55. O'Reilly, M.S., Holmgren, L., Chen, C., and Folkman, J. (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2, 689-692.
56. Parangi, S., Dietrich, W., Christofori, G., Lander, E., and Hanahan, D. (1995). Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic mouse model of islet cell carcinoma. Cancer Res. 55, 6071-6076.
57. Parangi, S., O'Reilly, M.S., Christofori, G., Holmgren, I., Grosfeld, J., Folkman, J., and Hanahan, D. (1996). Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA 93, 2002-2007.
58. Pepper, M.S., Ferrara, N., Orci, L., and Montessano, R. (1992). Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. 189, 824-831.
59. Rak, J.W., St. Croix, B.D., and Kerbel, R.S. (1995). Consequences of angiogenesis for tumor progression, metastasis, and cancer therapy. Anticancer Drugs 6, 3-18.
60. Rastinejad, F., Polverini, P.J., and Bouck, N.P. (1989). Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56, 345-355.
61. Risau, W. (1995). Differentiation of endothelium. FASEB J. 9, 926-933.
62. Risau, W., and Flamme, I. (1995). Vasculogenesis. Annu. Rev. Cell Dev. Biol. 11, 73-91.
63. Sato, Y., Abe, M., and Takaki, R. (1990). Platelet factor-4 blocks the binding of basic fibroblast growth factor to the receptor and inhibits the spontaneous migration of vascular endothelial cells. Biochem. Biophys. Res. Commun. 172, 595-600.
64. Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., and Dvorak, H.F. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985.
65. Sharp, R.J., Byers, H.R., Scott, C.F., Bauer, S.I., and Maione, T.E. (1990). Growth inhibition of murine melanoma and human colon carcinoma by recombinant human PF-4. J. Natl. Cancer Inst. 82, 848-853.
66. Shweike, D., Itin, A., Soffer, D., and Keshet, E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845.
67. Shweiki, D., Neeman, M., Itin, A., and Keshet, E. (1995). Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc. Natl. Acad. Sci. USA 92, 768-772.
68. Sidky, Y.A., and Borden, E.C. (1987). Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 47, 5155-5161.
69. Sippola-Thiele, M., Hanahan, D., and Howley, P.M. (1988). Cell heritable stages of tumor progression in transgenic mice harboring the bovine papillomavirus type 1 genome. Mol. Cell Biol. 9, 925-934.
70. Smith-McCune, K., and Weidner, N. (1994). Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 54, 800-804.
71. Stein, I., Neeman, M., Shweike, D., Itin, A., and Keshet, E. (1995). Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol. Cell Biol. 15, 5363-5368.
72. Taylor, S., and Folkman, J. (1982). Protamine is an inhibitor of angiogenesis. Nature 297, 307-312.
73. Teicher, B.A., Sotomayor, E.A., and Huang, Z.D. (1992). Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 52, 6702-6704.
74. Teitelman, G., Alpert, S., and Hanahan, D. (1988). Proliferation, senescence, and neoplastic progression of β cells in hyperplastic pancreatic islets. Cell 52, 97-105.
75. Tolsma, S.S., Volpert, O.V., Good, D.J., Frazier, W.A., Polverini, P.J., and Bouck, N. (1993). Peptides derived from two separate domains of the matrix protein thrombospondin-1 have antiangiogenic activity. J. Cell Biol. 122, 497-511.
76. Van Meir, E.G., Polverini, P.J., Chazin, V.R., Su Huang, H.-J., de Tribolet, N., and Cavenee, W.K. (1994). Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nature Genet. 8, 171-176.
77. Volpert, O.V., Stellmach, V., and Bouck, N. (1995). The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res. Treat. 36, 119-126.
78. Weidner, N., Semple, J.P., Welch, W.R., and Folkman, J. (1991). Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1-8.
79. Weidner, N., Folkman, J., Pozza, F., Bevilaqua, P., Allred, E.N., Moore, D.H., Meli, S., and Gasparini, G. (1992). Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84, 1875-1887.
80. Weidner, N., Carroll, P.R., Flax, J., Blumenfeld, W., and Folkman, J. (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143, 401-409.